Influential state senators in Kentucky, Virginia, and Florida have introduced bills recently that would prohibit drug manufacturer restrictions on 340B [...] …
Category: Pharma Industry
Amid expected congressional gridlock, there is a much higher likelihood of state legislative action on 340B contract pharmacies than federal [...] …
Drugmaker Novo Nordisk’s deal with Arkansas restoring 340B discounts in the contract pharmacy setting until a coming appeals court ruling, [...] …
In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package, lobbyists [...] …
Drugmaker Gilead Sciences will expand its data reporting requirements for 340B pricing on branded hepatitis C products to contract pharmacies [...] …
Drugmaker Johnson & Johnson will offer refunds to 340B providers related to the purchases of four of its drugs, including [...] …
In 2023, the battle over the use of contract pharmacy arrangements by 340B providers was marked by increasing drugmaker restrictions, [...] …
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...] …
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...] …
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...] …